GlassScriptPhysician profile
Luis Delgado
NPI 1114922499
$6,656.51
in general payments reported to CMS, 2019-2025
38 companies · $746 in 2025
The $746 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $1,123 · 2021: $962 · 2022: $724 · 2023: $811 · 2024: $891 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,171.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $552.09 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $542.21 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Janssen Pharmaceuticals, INC | $538.67 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $517.62 | 2019-2021 | |
| Amgen INC. | $342.68 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $266.57 | 2023-2025 | |
| Abbvie INC. | $262.70 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $231.13 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $228.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.38 | 2021-2025 | Jardiance |
| Allergan, INC. | $215.67 | 2019-2020 | |
| Medtronic USA, INC. | $170.86 | 2019 | |
| Acclarent, INC | $156.52 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $139.04 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.